Compare ONB & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | ONB | ABVX |
|---|---|---|
| Founded | 1834 | 2013 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Major Banks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.4B | 7.7B |
| IPO Year | 2012 | 2022 |
| Metric | ONB | ABVX |
|---|---|---|
| Price | $25.49 | $87.73 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 15 | 12 |
| Target Price | $28.90 | ★ $163.58 |
| AVG Volume (30 Days) | ★ 4.8M | 852.6K |
| Earning Date | 10-21-2026 | 09-21-2026 |
| Dividend Yield | ★ 2.33% | N/A |
| EPS Growth | ★ 6.55 | N/A |
| EPS | ★ 1.90 | N/A |
| Revenue | ★ $125,616,000.00 | N/A |
| Revenue This Year | $12.81 | N/A |
| Revenue Next Year | $4.92 | $1,695.54 |
| P/E Ratio | $13.10 | ★ N/A |
| Revenue Growth | ★ 6.07 | N/A |
| 52 Week Low | $19.60 | $69.81 |
| 52 Week High | $27.36 | $148.83 |
| Indicator | ONB | ABVX |
|---|---|---|
| Relative Strength Index (RSI) | 54.11 | 45.43 |
| Support Level | $25.40 | $83.83 |
| Resistance Level | $25.80 | $97.99 |
| Average True Range (ATR) | 0.63 | 3.75 |
| MACD | 0.05 | 0.51 |
| Stochastic Oscillator | 52.71 | 31.39 |
Old National Bancorp is a provider of lending and deposit services. The bank offers comprehensive wealth management, trust, investment advisory, brokerage, and foreign currency services. For businesses, it provides treasury management, merchant, and capital markets services as well as community development lending and equity investment solutions intended to produce jobs and revitalize its communities. It earns interest income on loans as well as fee income from the origination of loans and from providing other services to its clients.
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. The company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD. The Group operates in a single operating segment: R&D of pharmaceutical products in order to market them in the future.